Our analyses of mutations with VAF higher than the one of the POLE/POLD1 mutations and of potential driver genes point towards alterations that could represent new targets whether they occur early during oncogenesis or are selected during the evolution of the tumor. The gene discussed is POLE; the disease is neoplasm.